KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Common Equity (2016 - 2025)

Eli Lilly (LLY) has disclosed Common Equity for 17 consecutive years, with $26.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 85.92% year-over-year to $26.5 billion, compared with a TTM value of $26.5 billion through Dec 2025, up 85.92%, and an annual FY2025 reading of $26.5 billion, up 85.92% over the prior year.
  • Common Equity was $26.5 billion for Q4 2025 at Eli Lilly, up from $23.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $26.5 billion in Q4 2025 and bottomed at -$4.3 billion in Q4 2023.
  • Average Common Equity over 5 years is $3.2 billion, with a median of $204.0 million recorded in 2021.
  • The sharpest move saw Common Equity soared 15954.05% in 2022, then crashed 4922.9% in 2023.
  • Year by year, Common Equity stood at $3.7 million in 2021, then skyrocketed by 15954.05% to $594.0 million in 2022, then tumbled by 828.45% to -$4.3 billion in 2023, then soared by 429.84% to $14.3 billion in 2024, then surged by 85.92% to $26.5 billion in 2025.
  • Business Quant data shows Common Equity for LLY at $26.5 billion in Q4 2025, $23.9 billion in Q3 2025, and -$55.4 million in Q2 2025.